Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 12/20 | 0.98 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.69 |
| ▸ | HTR2B | P41595 | 3/20 | 0.69 |
| ▸ | HTR2C | P28335 | 2/20 | 0.69 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.58 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19503293 | 0.99 | P2RY1 (1.00) | P2RY1P2RY2ADORA3HTR2BHTR2C | |
| SCHEMBL29318022 | 0.93 | P2RY1 (0.86) | P2RY1P2RY2ADORA3HTR2BHTR2C | |
| SCHEMBL19807425 | 0.92 | P2RY1 (0.84) | P2RY1P2RY2ADORA3HTR2BHTR2C | |
| SCHEMBL19464972 | 0.91 | P2RY1 (0.85) | P2RY1P2RY2ADORA3HTR2BHTR2C | |
| SCHEMBL19459517 | 0.91 | P2RY1 (0.82) | P2RY1P2RY2ADORA3HTR2BHTR2C | |
| SCHEMBL19459473 | 0.90 | P2RY1 (0.83) | P2RY1P2RY2ADORA3HTR2BHTR2C | |
| SCHEMBL19807534 | 0.89 | P2RY1 (0.79) | P2RY1P2RY2ADORA3HTR2BHTR2C | |
| SCHEMBL21710863 | 0.87 | P2RY1 (0.98) | P2RY1P2RY2ADORA3P2RY11 | |
| SCHEMBL26934770 | 0.87 | P2RY1 (0.98) | P2RY1P2RY2ADORA3P2RY11 | |
| SCHEMBL19459900 | 0.87 | P2RY1 (0.98) | P2RY1P2RY2ADORA3P2RY11ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3445368-B1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |